899 related articles for article (PubMed ID: 15619665)
1. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
Tsujisawa T; Inoue H; Nishihara T
J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
[TBL] [Abstract][Full Text] [Related]
2. Fibroblasts express RANKL and support osteoclastogenesis in a COX-2-dependent manner after stimulation with titanium particles.
Wei X; Zhang X; Zuscik MJ; Drissi MH; Schwarz EM; O'Keefe RJ
J Bone Miner Res; 2005 Jul; 20(7):1136-48. PubMed ID: 15940366
[TBL] [Abstract][Full Text] [Related]
3. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
4. SC-19220, a prostaglandin E2 antagonist, inhibits osteoclast formation by 1,25-dihydroxyvitamin D3 in cell cultures.
Inoue H; Tsujisawa T; Fukuizumi T; Kawagishi S; Uchiyama C
J Endocrinol; 1999 May; 161(2):231-6. PubMed ID: 10320820
[TBL] [Abstract][Full Text] [Related]
5. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
6. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E2 strongly inhibits human osteoclast formation.
Take I; Kobayashi Y; Yamamoto Y; Tsuboi H; Ochi T; Uematsu S; Okafuji N; Kurihara S; Udagawa N; Takahashi N
Endocrinology; 2005 Dec; 146(12):5204-14. PubMed ID: 16150915
[TBL] [Abstract][Full Text] [Related]
8. Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice.
Li X; Pilbeam CC; Pan L; Breyer RM; Raisz LG
Bone; 2002 Apr; 30(4):567-73. PubMed ID: 11934647
[TBL] [Abstract][Full Text] [Related]
9. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs.
Suzawa T; Miyaura C; Inada M; Maruyama T; Sugimoto Y; Ushikubi F; Ichikawa A; Narumiya S; Suda T
Endocrinology; 2000 Apr; 141(4):1554-9. PubMed ID: 10746663
[TBL] [Abstract][Full Text] [Related]
10. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
11. Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro.
Li X; Okada Y; Pilbeam CC; Lorenzo JA; Kennedy CR; Breyer RM; Raisz LG
Endocrinology; 2000 Jun; 141(6):2054-61. PubMed ID: 10830290
[TBL] [Abstract][Full Text] [Related]
12. Important role of EP4, a subtype of prostaglandin (PG) E receptor, in osteoclast-like cell formation from mouse bone marrow cells induced by PGE2.
Ono K; Akatsu T; Murakami T; Nishikawa M; Yamamoto M; Kugai N; Motoyoshi K; Nagata N
J Endocrinol; 1998 Sep; 158(3):R1-5. PubMed ID: 9846175
[TBL] [Abstract][Full Text] [Related]
13. Regulatory effects of interleukin-1beta and prostaglandin E2 on expression of receptor activator of nuclear factor-kappaB ligand in human periodontal ligament cells.
Nukaga J; Kobayashi M; Shinki T; Song H; Takada T; Takiguchi T; Kamijo R; Hasegawa K
J Periodontol; 2004 Feb; 75(2):249-59. PubMed ID: 15068113
[TBL] [Abstract][Full Text] [Related]
14. Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro.
Tomita M; Li X; Okada Y; Woodiel FN; Young RN; Pilbeam CC; Raisz LG
Bone; 2002 Jan; 30(1):159-63. PubMed ID: 11792579
[TBL] [Abstract][Full Text] [Related]
15. Selective regulation of RNK-16 cell matrix metalloproteinases by the EP4 subtype of prostaglandin E2 receptor.
Zeng L; An S; Goetzl EJ
Biochemistry; 1996 Jun; 35(22):7159-64. PubMed ID: 8679543
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
17. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
18. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
19. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.
Timoshenko AV; Xu G; Chakrabarti S; Lala PK; Chakraborty C
Exp Cell Res; 2003 Oct; 289(2):265-74. PubMed ID: 14499627
[TBL] [Abstract][Full Text] [Related]
20. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
